NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company provides a comprehensive suite of testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. Its portfolio includes cytogenetics testing to study chromosomes and their relationship to diseases, fluorescence in-situ hybridization (FISH) testing to detect specific DNA sequences, flow cytometry to measure cell population characteristics, immunohistochemistry and digital imaging to localize cellular proteins, and molecular testing to analyze DNA and RNA. Additionally, it offers morphologic analysis for diagnosis under a microscope and testing services to support pharmaceutical clients' oncology programs from discovery through commercialization.

NeoGenomics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol NEO. The company's shares are traded in US Dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing requirements and reporting standards, providing investors with a regulated trading environment.

NeoGenomics operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company is involved in providing diagnostic testing services and research support, primarily focused on cancer. As a diagnostics and research firm, it plays a critical role in helping healthcare providers detect, diagnose, and monitor cancer through advanced laboratory testing. Its services are essential for personalized medicine and oncology research, distinguishing it from general healthcare providers.

NeoGenomics is headquartered in Fort Myers, Florida, United States. The company was founded in 2001 and operates a network of cancer-focused testing laboratories across the United States and the United Kingdom. Its services are available to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories in these regions. By serving both the US and UK markets, NeoGenomics has an international footprint in the oncology diagnostics space.

NeoGenomics generates revenue by offering a wide range of cancer-focused laboratory testing services to healthcare providers and pharmaceutical companies. Its clients include hospitals, academic centers, pathologists, oncologists, clinicians, and clinical laboratories. The company charges for each test performed, such as cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular testing, and morphologic analysis. Additionally, it provides specialized testing services to support pharmaceutical clients' oncology programs from discovery through commercialization, which likely involves contract-based revenue. By serving both clinical and research needs, NeoGenomics has diversified revenue streams within the oncology diagnostics market.